Ontology type: schema:ScholarlyArticle
2019-03-29
AUTHORSFernando Rivera, C. Romero, P. Jimenez-Fonseca, M. Izquierdo-Manuel, A. Salud, E. Martínez, M. Jorge, V. Arrazubi, J. C. Méndez, P. García-Alfonso, M. Reboredo, J. Barriuso, N. Muñoz-Unceta, R. Jimeno, C. López
ABSTRACTPURPOSE: The phase III ToGA trial established cisplatin, fluoropyrimidine and trastuzumab as the standard treatment in HER2-positive advanced gastric cancer (AGC). However, as demonstrated in HER2-negative AGC, oxaliplatin-based regimens could improve tolerance remaining effective. The aim of this trial was to explore the potential activity and safety of capecitabine, oxaliplatin (XELOX) and trastuzumab in patients with HER-2 positive advanced gastric cancer. METHODS: We conducted a multicentre, prospective, non-randomised, non-controlled, open-label and national (Spanish) phase II study. Patients with HER2-positive advanced gastric or gastro-oesophageal junction (EGJ) cancer received XELOX and trastuzumab as first-line treatment. Primary endpoint was objective tumour response rate (ORR). RESULTS: 45 patients from ten hospitals in Spain were included from September 2011 to December 2013. Median age was 65 years, 82.2% were male, 69% had gastric cancer and 31% had EGJ tumours. At a median follow-up of 13.7 months (7.1-20.9), the estimated median progression-free survival and overall survival were 7.1 (95% CI 5.5-8.7) and 13.8 months (95% CI 10.1-17.4), respectively, with 8.9%, 37.8% and 31.1% of patients achieving complete response, partial response and stable disease. Regarding safety, 44.4% of the patients had grade 3 or greater adverse events, being the most frequent diarrhoea (26.6%), fatigue (15.5%), nausea (20%) and vomiting (13.3%). Only two patients (4.4%) developed asymptomatic grade 2 left ventricle ejection fraction reduction. CONCLUSIONS: XELOX-trastuzumab is a promising and effective therapy as first-line treatment for patients with HER2-positive AGC, with comparable results to the ones obtained with other "platinum-based" regimens. This scheme is feasible and tolerable with a low incidence of cardiac toxicity. More... »
PAGES1-7
http://scigraph.springernature.com/pub.10.1007/s00280-019-03820-7
DOIhttp://dx.doi.org/10.1007/s00280-019-03820-7
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1113100936
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/30927036
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Oncology and Carcinogenesis",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Marqu\u00e9s de Valdecilla University Hospital",
"id": "https://www.grid.ac/institutes/grid.411325.0",
"name": [
"Medical Oncology Department, Hospital Universitario Marqu\u00e9s de Valdecilla, Avda Valdecilla SN, 39008, Santander, Spain"
],
"type": "Organization"
},
"familyName": "Rivera",
"givenName": "Fernando",
"type": "Person"
},
{
"affiliation": {
"name": [
"Medical Oncology Department, POVISA, Vigo, Spain"
],
"type": "Organization"
},
"familyName": "Romero",
"givenName": "C.",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Central University Hospital of Asturias",
"id": "https://www.grid.ac/institutes/grid.411052.3",
"name": [
"Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain"
],
"type": "Organization"
},
"familyName": "Jimenez-Fonseca",
"givenName": "P.",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Central University Hospital of Asturias",
"id": "https://www.grid.ac/institutes/grid.411052.3",
"name": [
"Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain"
],
"type": "Organization"
},
"familyName": "Izquierdo-Manuel",
"givenName": "M.",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Hospital Universitari Arnau de Vilanova",
"id": "https://www.grid.ac/institutes/grid.411443.7",
"name": [
"Medical Oncology Department, Hospital Arnau de Vilanova, Lleida, Spain"
],
"type": "Organization"
},
"familyName": "Salud",
"givenName": "A.",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Marqu\u00e9s de Valdecilla University Hospital",
"id": "https://www.grid.ac/institutes/grid.411325.0",
"name": [
"Medical Oncology Department, Hospital Universitario Marqu\u00e9s de Valdecilla, Avda Valdecilla SN, 39008, Santander, Spain"
],
"type": "Organization"
},
"familyName": "Mart\u00ednez",
"givenName": "E.",
"type": "Person"
},
{
"affiliation": {
"name": [
"Medical Oncology Department, Hospital Xeral Cies, Vigo, Spain"
],
"type": "Organization"
},
"familyName": "Jorge",
"givenName": "M.",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Complejo Hospitalario de Navarra",
"id": "https://www.grid.ac/institutes/grid.497559.3",
"name": [
"Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain"
],
"type": "Organization"
},
"familyName": "Arrazubi",
"givenName": "V.",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Centro Oncol\u00f3gico de Galicia",
"id": "https://www.grid.ac/institutes/grid.418394.3",
"name": [
"Medical Oncology Department, Centro Oncol\u00f3gico de Galicia, Coru\u00f1a, Spain"
],
"type": "Organization"
},
"familyName": "M\u00e9ndez",
"givenName": "J. C.",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Hospital General Universitario Gregorio Mara\u00f1\u00f3n",
"id": "https://www.grid.ac/institutes/grid.410526.4",
"name": [
"Medical Oncology Department, Hospital Gregorio Mara\u00f1\u00f3n, Madrid, Spain"
],
"type": "Organization"
},
"familyName": "Garc\u00eda-Alfonso",
"givenName": "P.",
"type": "Person"
},
{
"affiliation": {
"name": [
"Medical Oncology Department, Complejo Hospitalario de A Coru\u00f1a, Coru\u00f1a, Spain"
],
"type": "Organization"
},
"familyName": "Reboredo",
"givenName": "M.",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Hospital Universitario La Paz",
"id": "https://www.grid.ac/institutes/grid.81821.32",
"name": [
"Medical Oncology Department, Hospital La Paz, Madrid, Spain"
],
"type": "Organization"
},
"familyName": "Barriuso",
"givenName": "J.",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Marqu\u00e9s de Valdecilla University Hospital",
"id": "https://www.grid.ac/institutes/grid.411325.0",
"name": [
"Medical Oncology Department, Hospital Universitario Marqu\u00e9s de Valdecilla, Avda Valdecilla SN, 39008, Santander, Spain"
],
"type": "Organization"
},
"familyName": "Mu\u00f1oz-Unceta",
"givenName": "N.",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Marqu\u00e9s de Valdecilla University Hospital",
"id": "https://www.grid.ac/institutes/grid.411325.0",
"name": [
"Medical Oncology Department, Hospital Universitario Marqu\u00e9s de Valdecilla, Avda Valdecilla SN, 39008, Santander, Spain"
],
"type": "Organization"
},
"familyName": "Jimeno",
"givenName": "R.",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Marqu\u00e9s de Valdecilla University Hospital",
"id": "https://www.grid.ac/institutes/grid.411325.0",
"name": [
"Medical Oncology Department, Hospital Universitario Marqu\u00e9s de Valdecilla, Avda Valdecilla SN, 39008, Santander, Spain"
],
"type": "Organization"
},
"familyName": "L\u00f3pez",
"givenName": "C.",
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1007/s12094-015-1456-y",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1008954201",
"https://doi.org/10.1007/s12094-015-1456-y"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s12094-015-1456-y",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1008954201",
"https://doi.org/10.1007/s12094-015-1456-y"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1186/s12885-016-2092-9",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1013426971",
"https://doi.org/10.1186/s12885-016-2092-9"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1056/nejmoa073149",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1014019609"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/s0140-6736(11)61873-4",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1016678387"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.2007.13.9378",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1023463275"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/j.ejca.2014.12.015",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1026314656"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1159/000335585",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1027896352"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00228-015-1828-9",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1031187796",
"https://doi.org/10.1007/s00228-015-1828-9"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/j.bulcan.2014.08.001",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1034665463"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/j.ejca.2012.12.027",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1036026674"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/s0140-6736(10)61121-x",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1044182432"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1097/coc.0b013e3181967db3",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1049684905"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1097/coc.0b013e3181967db3",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1049684905"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1097/coc.0b013e3181967db3",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1049684905"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1093/annonc/mdn717",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1053015328"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.3892/mco.2015.609",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1071519379"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.2015.33.3_suppl.107",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1083954707"
],
"type": "CreativeWork"
}
],
"datePublished": "2019-03-29",
"datePublishedReg": "2019-03-29",
"description": "PURPOSE: The phase III ToGA trial established cisplatin, fluoropyrimidine and trastuzumab as the standard treatment in HER2-positive advanced gastric cancer (AGC). However, as demonstrated in HER2-negative AGC, oxaliplatin-based regimens could improve tolerance remaining effective. The aim of this trial was to explore the potential activity and safety of capecitabine, oxaliplatin (XELOX) and trastuzumab in patients with HER-2 positive advanced gastric cancer.\nMETHODS: We conducted a multicentre, prospective, non-randomised, non-controlled, open-label and national (Spanish) phase II study. Patients with HER2-positive advanced gastric or gastro-oesophageal junction (EGJ) cancer received XELOX and trastuzumab as first-line treatment. Primary endpoint was objective tumour response rate (ORR).\nRESULTS: 45 patients from ten hospitals in Spain were included from September 2011 to December 2013. Median age was 65 years, 82.2% were male, 69% had gastric cancer and 31% had EGJ tumours. At a median follow-up of 13.7\u00a0months (7.1-20.9), the estimated median progression-free survival and overall survival were 7.1 (95% CI 5.5-8.7) and 13.8\u00a0months (95% CI 10.1-17.4), respectively, with 8.9%, 37.8% and 31.1% of patients achieving complete response, partial response and stable disease. Regarding safety, 44.4% of the patients had grade 3 or greater adverse events, being the most frequent diarrhoea (26.6%), fatigue (15.5%), nausea (20%) and vomiting (13.3%). Only two patients (4.4%) developed asymptomatic grade 2 left ventricle ejection fraction reduction.\nCONCLUSIONS: XELOX-trastuzumab is a promising and effective therapy as first-line treatment for patients with HER2-positive AGC, with comparable results to the ones obtained with other \"platinum-based\" regimens. This scheme is feasible and tolerable with a low incidence of cardiac toxicity.",
"genre": "research_article",
"id": "sg:pub.10.1007/s00280-019-03820-7",
"inLanguage": [
"en"
],
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1088364",
"issn": [
"0344-5704",
"1432-0843"
],
"name": "Cancer Chemotherapy and Pharmacology",
"type": "Periodical"
}
],
"name": "Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial",
"pagination": "1-7",
"productId": [
{
"name": "readcube_id",
"type": "PropertyValue",
"value": [
"739bb4a703997f3438d9f4b18fa3f3c6cdb1a9582e93d7925732a63bb33384fb"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"30927036"
]
},
{
"name": "nlm_unique_id",
"type": "PropertyValue",
"value": [
"7806519"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s00280-019-03820-7"
]
},
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1113100936"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s00280-019-03820-7",
"https://app.dimensions.ai/details/publication/pub.1113100936"
],
"sdDataset": "articles",
"sdDatePublished": "2019-04-11T13:24",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000369_0000000369/records_68959_00000002.jsonl",
"type": "ScholarlyArticle",
"url": "https://link.springer.com/10.1007%2Fs00280-019-03820-7"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03820-7'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03820-7'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03820-7'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03820-7'
This table displays all metadata directly associated to this object as RDF triples.
218 TRIPLES
21 PREDICATES
41 URIs
18 LITERALS
7 BLANK NODES